Blueprint Genetics is committed to providing the highest-quality genetic testing for our customers.
First, in order to achieve and demonstrate our testing quality, we have performed a comprehensive and fully traceable analytic validation. The analytic validation includes a description of technologies that are used in the diagnostic process, full disclosure of the publicly available materials and data set used, applied statistical approaches, the exact definition of the target regions, and a complete assessment of the performance metrics for different variant types.
Second, to communicate our testing quality effectively, we have prepared a detailed documentation of the analytic validation experiments and results, and provide all relevant data on our website for each individual panel and test type to allow our customers to openly audit our offering.
Third, our compilation of in-depth quality data in each test report enables the clinician to directly evaluate the test’s performance and have confidence that all actionable information has been provided when deciding the clinical follow-up.
Being fully transparent, Blueprint Genetics is setting a high standard for genetic testing. We invite our customers to join the effort of improving the diagnostics of inherited disorders for the benefit of the patients.
You can read more about the Transparency at Blueprint Genetics by following the links in the table below:
White papers & Guides
Blueprint Genetics is ISO 15189 and CAP accredited genetic diagnostic laboratory.
Quality Management System
The Quality Management System of Blueprint Genetics is designed to adapt the commonly used principles of effective quality management. Blueprint Genetics NGS pipeline is ISO 15189-accredited and is compliant in every step from sample arrival to clinical interpretation. The ISO 15189 standard accreditation is carried out by FINAS. The information about the scope is available on the website: finas.fi.
Whole exome sequencing (WES)
Analytic validity (Analytic validation report) of Blueprint Genetics’ genetic tests has been demonstrated for SNVs, INDELs, as well as CNVs utilizing reference samples with high-quality variant calls and clinical samples. Analytic validation results show that Blueprint Genetics NGS assays achieve 0.997 sensitivity and 0.999 specificity for detection of SNVs and >0.97 sensitivity for detection of INDELs of up to 50 bases. Blueprint Genetics data analysis covers high-resolution CNV analysis showing clinical sensitivity of 0.92 for detection of 1 exon-level deletions.
Blueprint Genetics participates in CAP proficiency testing programs. In addition, Blueprint Genetics has an internal Quality Control system, which consists of management of facilities, equipment, materials, and software, as well as in-process quality control of methods, examinations, and data analysis. Quality control sample DNA is added to each diagnostic sequencing test and sequence coverage is monitored and evaluated for each sample. Results of the test are accepted if >98% of target regions are covered with at least 20x sequencing depth and the control sample in the sequencing run shows the required sensitivity to detect SNVs (>0.995) and INDELs (>0.950).
The final step in the analysis is orthogonal confirmation. Sequence variants classified as pathogenic, likely pathogenic, and variants of uncertain significance (VUS) are confirmed using bi-directional Sanger sequencing when they do not meet our stringent NGS quality metrics for a true positive call. Reported heterozygous and homo-/hemizygous copy number variations with a size <10 and <3 exons are confirmed by orthogonal methods such as dPCR if the specific CNV has been seen and confirmed less than 3 times at Blueprint Genetics.
Variant Interpretation and Clinical Statement
Blueprint Genetics’ policy for variant classification is based on published ACMG guidelines. Blueprint Genetics delivers comprehensive clinical statements including detailed interpretation of key findings. All of our reports include a summary of the clinical history, a detailed description of the methodology, and a clear summary of the identified, relevant variants following international best practice guidelines (CMGS / ACMG). It also includes carefully weighed interpretation of the genotype-phenotype associations with links to the cited publications and recommendations for family screening. At Blueprint Genetics, we are continuously improving our testing processes to meet your patient’s needs with the most valuable diagnostic service.
Operations in North America
Our US facility in Seattle provides customer support, clinical genetics support, billing, and sample reception for our customers in North and South America. After receiving the samples, our office ships them with a secure courier service to our CLIA-certified and CAP- and ISO-15189 accredited facility in Helsinki, Finland. Our service model, which has been evaluated by US authorities for CLIA and CAP, ensures our ability to maintain the highest quality standards.